Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Roche's Fuzeon offers hope...to the 20% of patients that receive it

19 Jul 04

New clinical research presented at the 15th International AIDS Conference (IAC) shows that Fuzeon is proving to be remarkably effective in the first long-term trial of its benefits.
Datamonitor

Difficulty Getting Interviews? – Write an Interview Winning CV!

14 Jul 04

What exactly is a Curriculum Vitae? Is it a List of your Skills and Experience? Is it a Mini Biography? Is it a chance to get someone to fully appreciate your Skills and Achievements? Truth be known, It’s none of these.
Lydia Holder

Advances in the development of corticotropin-releasing-hormone (CRH) receptor agonists as candidate analgesics

13 Jul 04

Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within the central nervous system.
LeadDiscovery

The emerging role of the IL-4/IL-3 cytokine receptor IL-4Ralpha in asthma

09 Jul 04

Analysts have recently predicted that the market for airway inflammatory diseases will increase by 35% to over $18 billion by 2011. A recent target evaluation report produced for the drug development sector concluded that the TH2-derived cytokines IL-4, and more so IL-13 represent promising targets. Both cytokines activate IL-4Ralpha to produce multiple functional changes observed in asthma patients. A recent report published in the Journal of Immunology elucidates the divergent mechanisms th
LeadDiscovery

Strong potential for cross risk-factor single pill therapies

09 Jul 04

Recently published data from the GENOA study has demonstrated that dyslipidemia is highly prevalent in hypertensive adults and that this condition is insufficiently treated in more than half of the cases. As Datamonitor's Laurent Chanroux explains, the results lend further support to cross risk-factor, single pill combination therapies such as Pfizer's Caduet...
Datamonitor

Early adopters of ePrescribing serve as models in a growing market

05 Jul 04

SureScripts, in partnership with the Massachusetts Medical Society, is launching an educational network providing physicians with information from the early adopters of ePrescribing technology. Datamonitor's Kimberly O'Malley argues that educational forums like this allow members to more efficiently evaluate and subsequently adopt electronic prescribing as a solution for their practices...
Datamonitor

METABOLIC SYNDROME REACHES EPIDEMIC LEVEL

05 Jul 04

Metabolic syndrome, a cluster of common metabolic disorders including obesity, pre-diabetes, abnormal lipid levels and high blood pressure, is now approaching epidemic proportions worldwide.
Datamonitor

Driving Drug Discovery through External R&D Resources

30 Jun 04

Post-Conference Workshop: Structuring the Deal-- Contract Development and Negotiations for Improved Results
Kelly Cavin

Emerging Drug Discovery Targets; June 28th

29 Jun 04

This edition of "Emerging Drug Discovery Targets" features new approaches to improving intestinal uptake of poorly absorbed therapeutics; a dual 5-LO inhibitor/H1 receptor antagonist for the treatment of asthma; Sitaxentan as an effective treatment of pulmonary arterial hypertension; Kv1.3 potassium channel blockade as an approach to insulin resistance; Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis; VEGF receptor tyr
LeadDiscovery

Novartis’/Schering’s VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584 as a candidate treatment of rheumatoid arthritis.

25 Jun 04

Rheumatoid arthritis is one of the more common autoimmune diseases. LeadDiscovery’s recent state of the art evaluation of rheumatoid arthritis therapeutics evaluates advances in our understanding of the etiology of the disease. One field of research extensively analyzed in this report is angiogenesis. Inhibitors of receptor tyrosine kinase with specific activity against the VEGFRs have been developed in an attempt to prevent angiogenesis. One such molecule is PTK787/ZK222584, synthesized and dev
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.